Evidence map›Paper›PMID 34110395›Full record

ArticleJAMA network open2021

Actual and Missed Opportunities for End-of-Life Care Discussions With Oncology Patients: A Qualitative Study.

Kristin E Knutzen, Olivia A Sacks, Olivia C Brody-Bizar, Genevra F Murray, Raina H Jain, Lindsay A Holdcroft, Shama S Alam, Matthew A Liu, Kathryn I Pollak, James A Tulsky and 1 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults With Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Kristin E KnutzenDepartment of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Olivia A SacksDepartment of Surgery, Boston Medical Center, Boston, Massachusetts.
Olivia C Brody-BizarDartmouth College, Hanover, New Hampshire.
Genevra F MurrayDepartment of General Medicine, Boston Medical Center, Boston, Massachusetts.
Raina H JainGeisel School of Medicine, Dartmouth College, Hanover, New Hampshire.
Lindsay A HoldcroftGeisel School of Medicine, Dartmouth College, Hanover, New Hampshire.
Shama S AlamPharmaceutical Product Development, Evidera, Bethesda, Maryland.
Matthew A LiuSchool of Medicine, University of California, San Diego, La Jolla.
Kathryn I PollakSchool of Medicine, Duke University, Durham, North Carolina.
James A TulskyDepartment of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts.
Amber E BarnatoThe Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
Dartmouth College · USBoston Medical Center · USBrigham and Women's Hospital · USDartmouth–Hitchcock Medical Center · USDuke University · USEmory University · USPharmaceutical Product Development (United States) · USUniversity of California, San Diego · US

Funding

Enhancing Patient-Oncologist CommunicationR01CA100387 · NCI · DUKE UNIVERSITY · PI POLLAK, KATHRYN I · 2003 to 2013
$6.1M
NCI NIH HHS R01 CA100387
6 · The paper itself

Abstract

Importance: Early discussion of end-of-life (EOL) care preferences improves clinical outcomes and goal-concordant care. However, most EOL discussions occur approximately 1 month before death, despite most patients desiring information earlier. Objective: To describe successful navigation and missed opportunities for EOL discussions (eg, advance care planning, palliative care, discontinuation of disease-directed treatment, hospice care, and after-death wishes) between oncologists and outpatients with advanced cancer. Design, Setting, and Participants: This study is a secondary qualitative analysis of outpatient visits audio-recorded between November 2010 and September 2014 for the Studying Communication in Oncologist-Patient Encounters randomized clinical trial. The study was conducted at 2 US academic medical centers. Participants included medical, gynecological, and radiation oncologists and patients with stage IV malignant neoplasm, whom oncologists characterized as being ones whom they "…would not be surprised if they were admitted to an intensive care unit or died within one year." Data were analyzed between January 2018 and August 2020. Exposures: The parent study randomized participants to oncologist- and patient-directed interventions to facilitate discussion of emotions. Encounters were sampled across preintervention and postintervention periods and all 4 treatment conditions. Main Outcomes and Measures: Secondary qualitative analysis was done of patient-oncologist dyads with 3 consecutive visits for EOL discussions, and a random sample of 7 to 8 dyads from 4 trial groups was analyzed for missed opportunities. Results: The full sample included 141 patients (54 women [38.3%]) and 39 oncologists (8 women [19.5%]) (mean [SD] age for both patients and oncologists, 56.3 [10.0] years). Of 423 encounters, only 21 (5%) included EOL discussions. Oncologists reevaluated treatment options in response to patients' concerns, honored patients as experts on their goals, or used anticipatory guidance to frame treatment reevaluation. In the random sample of 31 dyads and 93 encounters, 35 (38%) included at least 1 missed opportunity. Oncologists responded inadequately to patient concerns over disease progression or dying, used optimistic future talk to address patient concerns, or expressed concern over treatment discontinuation. Only 4 of 23 oncologists (17.4%) had both an EOL discussion and a missed opportunity. Conclusions and Relevance: Opportunities for EOL discussions were rarely realized, whereas missed opportunities were more common, a trend that mirrored oncologists' treatment style. There remains a need to address oncologists' sensitivity to EOL discussions, to avoid unnecessary EOL treatment.

Indexed as

CommunicationPhysician-Patient RelationsAdultAdvance Care PlanningAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasmsOncologistsPatient Care PlanningPatientsQualitative ResearchTerminal Care

Identifiers

PMID34110395
PMCPMC8193430
OpenAlexW3169489734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.